Entries by https://www.sandoz.com/rss/feeds/news/media-releases.xml

Sandoz launches first generic pirfenidone in US for patients with idiopathic pulmonary fibrosis, growing its respiratory portfolio

Pirfenidone is used to treat idiopathic pulmonary fibrosis (IPF),1 a progressive disease that causes irreversible lung scarring and makes it difficult to breathe2Approximately 140,000 Americans live with IPF, a rare disease with no cure, and 50,000 new…

Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook

Ad hoc announcement pursuant to Art. 53 LRQ1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD)Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core operating income +5% (cc, 0% USD)Strong performance of key growth br…

Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio

Brimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1Ocular hypertension affects over 5% of all adults2; the eye does not properly drain fluid, causing eye pressure to buil…

Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)

Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025 Both parties strengthening focus on antibiotic stewardship and planning to engage…

Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)

Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025 Both parties strengthening focus on antibiotic stewardship and planning to engage…

Sandoz targets growth opportunities in respiratory and complex generics through acquisition of respiratory device company Coalesce

Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex genericsRespiratory diseases are leading cause of death and disability and impose huge financial b…

Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine

Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4Cost savings from Lenalidomide Sandoz can expand treatment options for patients with haemato-oncology conditions1,2Sandoz is comm…

Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021

Ad hoc announcement pursuant to Art. 53 LRQ4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD)IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12% USD)Sandoz sales grew +2% (cc, 0% USD) and core operati…

Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021

Ad hoc announcement pursuant to Art. 53 LRQ4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD)IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12% USD)Sandoz sales grew +2% (cc, 0% USD) and core operati…

Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA

Submission is supported by comprehensive package of analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc. Breast cancer is one of most common types of cancer in women, accounting for over 355,000 new ca…